Paper42101653
Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.
Zhang G and 9 others. Cancer Immunol Immunother, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2. Papers, record 42101653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42101653
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| TRPV Cation Channels | Major topic |
| T-Lymphocytes | Major topic |
| Galectin 3 | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Calcium Channels | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Recombinant Proteins | |
| Cell Line, Tumor | |
| Lymphocyte Activation |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| XWKYHT20240123 | Science and Technology Project of Xuzhou Municipal Health Commission | PubMed | ||
| 82473333 | National Natural Science Foundation of China | PubMed | ||
| 81972242 | National Natural Science Foundation of China | PubMed | ||
| BE2023689 | Jiangsu Province Social Development Projects | PubMed | ||
| QL-YB032 | XZHMU-QL Joint Research Fund | PubMed | ||
| LCZX202501 | Construction Project of High Level Hospital of Jiangsu Province | PubMed | ||
| BK20150216 | Natural Science Foundation of Jiangsu Province | PubMed | ||
| 20KJA320006 | Natural Science Key Project of Jiangsu Provincial Education Department | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 42616099 | Correction: Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2. | https://conductscience.org/library/papers/42616099 |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32735779 | Engineering CAR-T Cells for Next-Generation Cancer Therapy. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32735779 | PubMed |
| 2 | 38295165 | N-glycosylation as a eukaryotic protective mechanism against protein aggregation. | Sci Adv | 2024 | https://conductscience.org/library/papers/38295165 | PubMed |
| 3 | 21574765 | Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel TRPV2. | Physiol Res | 2012 | https://conductscience.org/library/papers/21574765 | PubMed |
| 4 | 12796408 | Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/12796408 | PubMed |
| 5 | 38353705 | Ion channel TRPV2 is critical in enhancing B cell activation and function. | J Exp Med | 2024 | https://conductscience.org/library/papers/38353705 | PubMed |
| 6 | 37548063 | Coengineering specificity, safety, and function into T cells for cancer immunotherapy. | Immunol Rev | 2023 | https://conductscience.org/library/papers/37548063 | PubMed |
| 7 | 23615321 | What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel? | FEBS J | 2013 | https://conductscience.org/library/papers/23615321 | PubMed |
| 8 | 35624021 | Turning cold tumors hot: from molecular mechanisms to clinical applications. | Trends Immunol | 2022 | https://conductscience.org/library/papers/35624021 | PubMed |
| 9 | 38816425 | TCAF1 promotes TRPV2-mediated Ca2+ release in response to cytosolic DNA to protect stressed replication forks. | Nat Commun | 2024 | https://conductscience.org/library/papers/38816425 | PubMed |
| 10 | 29072683 | Plasminogen kringle 5 suppresses gastric cancer via regulating HIF-1α and GRP78. | Cell Death Dis | 2017 | https://conductscience.org/library/papers/29072683 | PubMed |
| 11 | 32612154 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. | Cell Mol Immunol | 2020 | https://conductscience.org/library/papers/32612154 | PubMed |
| 12 | 38382538 | Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance. | Annu Rev Immunol | 2024 | https://conductscience.org/library/papers/38382538 | PubMed |
| 13 | 22419253 | The immune contexture in human tumours: impact on clinical outcome. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22419253 | PubMed |
| 14 | 14991772 | RGA protein associates with a TRPV ion channel during biosynthesis and trafficking. | J Cell Biochem | 2004 | https://conductscience.org/library/papers/14991772 | PubMed |
| 15 | 23420671 | The role of transient receptor potential vanilloid type-2 ion channels in innate and adaptive immune responses. | Front Immunol | 2013 | https://conductscience.org/library/papers/23420671 | PubMed |
| 16 | 35638332 | Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling. | EMBO J | 2022 | https://conductscience.org/library/papers/35638332 | PubMed |
| 17 | 23470321 | Molecular mechanisms of T cell co-stimulation and co-inhibition. | Nat Rev Immunol | 2013 | https://conductscience.org/library/papers/23470321 | PubMed |
| 18 | 36689620 | Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming. | Cancer Immunol Res | 2023 | https://conductscience.org/library/papers/36689620 | PubMed |
| 19 | 25903376 | Functional expression of TRPV channels in T cells and their implications in immune regulation. | FEBS J | 2015 | https://conductscience.org/library/papers/25903376 | PubMed |
| 20 | 34873817 | Towards understanding the extensive diversity of protein N-glycan structures in eukaryotes. | Biol Rev Camb Philos Soc | 2022 | https://conductscience.org/library/papers/34873817 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42101653
GET https://conductscience.org/api/papers/v1/42101653/references?page=2